GlassScriptPhysician profile
Jim Carmical
NPI 1194145607
$2,770.18
in general payments reported to CMS, 2019-2025
29 companies · $411 in 2025
The $411 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $184 · 2021: $482 · 2022: $128 · 2023: $884 · 2024: $681 · 2025: $411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,976.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,975.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $896.59 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $282.56 | 2020-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $197.85 | 2020-2025 | Airsupra, Breztri |
| Pfizer INC. | $195.71 | 2020-2025 | |
| Novo Nordisk INC | $176.26 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Otsuka America Pharmaceutical, INC. | $141.17 | 2023-2024 | Rexulti |
| Lilly USA, LLC | $97.52 | 2022-2024 | Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $90.55 | 2020-2023 | Trintellix |
| Amgen INC. | $79.42 | 2020-2024 | Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.52 | 2021-2023 | Xifaxan, Trulance |
| Astellas Pharma US INC | $67.37 | 2021-2024 | Veozah |
| Exact Sciences Corporation | $66.48 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $66.18 | 2020-2024 | Vaxneuvance, Gardasil, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $60.00 | 2020-2024 | Eliquis |
| Esperion Therapeutics, INC. | $36.65 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $35.33 | 2023 | Ajovy, Austedo |
| Novartis Pharmaceuticals Corporation | $22.51 | 2020-2021 | |
| Lundbeck LLC | $19.69 | 2025 | Rexulti |
| Mylan Specialty L.P. | $19.09 | 2023 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.89 | 2023 | Jardiance |
| Dexcom, INC. | $16.74 | 2024 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.45 | 2025 | Caplyta |
| Axsome Therapeutics, INC. | $15.51 | 2025 | Auvelity |
| Biohaven Pharmaceuticals, INC. | $14.31 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.75 | 2023 | Seglentis |
| Janssen Pharmaceuticals, INC | $13.74 | 2022 | |
| Horizon Therapeutics Plc | $12.97 | 2021 | |
| Sanofi-Aventis U.S. LLC | $12.88 | 2023 | |
| Allergan, INC. | $12.49 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jim Carmical listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.